28
Participants
Start Date
August 8, 2016
Primary Completion Date
May 16, 2017
Study Completion Date
October 17, 2017
GSK1278863
GSK1278863 will be provided as round, standard biconvex, white film coated tablets containing 1 mg, 2 mg, 4 mg or 6 mg of GSK1278863 as active ingredient.
Iron
Subjects will receive supplemental iron therapy if ferritin is \<=100 ng/mL and TSAT is \<=20%. The investigator (or subinvestigator) will choose the route of administration and dose of prescription iron.
GSK Investigational Site, Aichi
GSK Investigational Site, Aichi
GSK Investigational Site, Fukuoka
GSK Investigational Site, Hokkaido
GSK Investigational Site, Ibaraki
GSK Investigational Site, Ibaraki
GSK Investigational Site, Ibaraki
GSK Investigational Site, Kagoshima
GSK Investigational Site, Kumamoto
GSK Investigational Site, Kyoto
GSK Investigational Site, Mie
GSK Investigational Site, Nagano
GSK Investigational Site, Nagano
GSK Investigational Site, Osaka
GSK Investigational Site, Ōita
GSK Investigational Site, Shiga
GSK Investigational Site, Yamagata
Lead Sponsor
GlaxoSmithKline
INDUSTRY